Skip to main
PASG

PASSAGE BIO (PASG) Stock Forecast & Price Target

PASSAGE BIO (PASG) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Passage Bio Inc is advancing its pipeline of genetic medicines aimed at treating rare, monogenic CNS disorders, with promising interim data from the upliFT-D study indicating sustained increases in key biomarkers such as CSF PGRN. The company’s proactive approach to amending trial protocols suggests a potential for earlier intervention in disease progression, which may enhance treatment benefits for patients. Furthermore, the strategic design for accelerated regulatory approval based on biomarker endpoints presents significant opportunities for reducing trial timelines and driving future growth in the genetic medicines sector.

Bears say

Passage Bio Inc faces several significant challenges that contribute to a negative outlook on its stock. There are concerns regarding potential delays in clinical timelines, particularly for its pipeline products PBGM01 and PBFT02, which could be exacerbated by unforeseen safety issues or lower-than-expected efficacy, directly impacting market sentiment and leading to downward revisions of financial estimates. Furthermore, the company's reliance on sufficient manufacturing capacity raises additional regulatory risks, which, if not managed effectively, could materially constrict forecasts and impede overall growth potential.

PASSAGE BIO (PASG) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PASSAGE BIO (PASG) Forecast

Analysts have given PASSAGE BIO (PASG) a Strong Buy based on their latest research and market trends.

According to 4 analysts, PASSAGE BIO (PASG) has a Strong Buy consensus rating as of Jan 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PASSAGE BIO (PASG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.